JNCE - Jounce Therapeutics, Inc.
| Previous Close | 4.7500 |
| Open | 4.7700 |
| Bid | 3.86 x 3100 |
| Ask | 3.80 x 1000 |
| Day's Range | 3.7700 - 4.7700 |
| 52 Week Range | 2.6600 - 29.2500 |
| Volume | 677,061 |
| Avg. Volume | 354,818 |
| Market Cap | 124.262M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.07 |
| Earnings Date | Aug 9, 2018 - Aug 11, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.50 |
- Thomson Reuters StreetEvents•13 days ago
Edited Transcript of JNCE.O earnings conference call or presentation 13-Nov-18 1:00pm GMT
Q3 2018 Jounce Therapeutics Inc Earnings Call
- GlobeNewswire•18 days ago
Jounce Therapeutics Completed Enrollment in First Cohort of Phase 1 Clinical Trial with its PD-1 Inhibitor, JTX-4014
CAMBRIDGE, Mass., Jan. 03, 2019 -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies.
- GlobeNewswire•19 days ago
Jounce Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 02, 2019 -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies.
- Insider Monkey•last month
Hedge Funds Are Crazy About Jounce Therapeutics, Inc. (JNCE)
We at Insider Monkey have gone over 700 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds’ and investors’ portfolio positions as of September 30th. In this article, we look at what those funds think of Jounce Therapeutics, Inc. (NASDAQ:JNCE) based on that […]
- GlobeNewswire•2 months ago
Report: Exploring Fundamental Drivers Behind Matrix Service, NantHealth, Earthstone Energy, Jounce Therapeutics, BeiGene, and Oxford Immunotec Global — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Zacks•2 months ago
Jounce Therapeutics, Inc. (JNCE) Reports Q3 Loss, Tops Revenue Estimates
Jounce Therapeutics, Inc. (JNCE) delivered earnings and revenue surprises of 32.35% and 13.50%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire•2 months ago
Jounce Therapeutics Reports Third Quarter 2018 Financial Results
- Dose escalation cohorts of JTX-2011 Phase 1/2 ICONIC trial, in combination with ipilimumab and in combination with pembrolizumab, on track - - IND filed and clearance to.
- GlobeNewswire•2 months ago
Jounce Therapeutics Presents Reverse Translational, Biomarker and Preclinical Data from ICOS Program at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting
Jounce Therapeutics, Inc. (JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that reverse translational and biomarker data derived from its ICONIC (ICOS AgONist Antibody for Immunotherapy in Cancer Patients) trial of JTX-2011 and preclinical data from the ICOS (Inducible T cell CO-Stimulator) program were presented at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting, being held November 9-11, 2018 in Washington, D.C. “The data presented at SITC’s 33rd Annual Meeting demonstrate the role of JTX-2011 in the emergence and agonism of ICOS hi CD4 T effector cells and provide further evidence in support of the biological and clinical activity of JTX-2011.
- GlobeNewswire•2 months ago
Jounce Therapeutics to Announce Third Quarter 2018 Financial Results and Host Conference Call on Tuesday, November 13, 2018
CAMBRIDGE, Mass., Nov. 06, 2018 -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies.
- Zacks•3 months ago
Analysts Estimate Jounce Therapeutics, Inc. (JNCE) to Report a Decline in Earnings: What to Look Out for
Jounce Therapeutics, Inc. (JNCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire•3 months ago
Jounce Therapeutics to Present Two Posters from the JTX-2011 Program at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting
CAMBRIDGE, Mass., Nov. 02, 2018 -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies.
- Zacks•5 months ago
Jounce Therapeutics, Inc. (JNCE) Reports Q2 Loss, Tops Revenue Estimates
Jounce Therapeutics, Inc. (JNCE) delivered earnings and revenue surprises of 62.16% and 55.36%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- ACCESSWIRE•5 months ago
Jounce Therapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 9, 2018 / Jounce Therapeutics, Inc. (NASDAQ: JNCE ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 9, 2018 at 8:00 AM Eastern ...
- ACCESSWIRE•6 months ago
Free Technical Research on Intrexon and Three More Biotech Equities
LONDON, UK / ACCESSWIRE / July 11, 2018 / If you want a free Stock Review on XON sign up now at www.wallstequities.com/registration. On Tuesday, July 10, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Seven out of nine sectors ended Tuesday's trading session in bullish territories.
- InvestorPlace•8 months ago
Agios Pharmaceuticals, Inc.Stock Is an Analyst Darling for Good Reason
As Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) closes at new highs, analysts are gushing over the company’s prospects. What is it about Agios stock that has the experts bullish on the company? Markets speculated that Celgene Corporation (NASDAQ:CELG) would buy Agios or Jounce Therapeutics, Inc. (NASDAQ:JNCE) back in April.
- ACCESSWIRE•8 months ago
Today's Research Reports on Stocks to Watch: Deciphera Pharmaceuticals and Jounce Therapeutics
NEW YORK, NY / ACCESSWIRE / June 5, 2018 / While shares of Deciphera skyrocketed yesterday and hit a new high on positive data results, shares of Jounce Therapeutics saw the opposite result on its own ...
